Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.
Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GE, Cornelissen JJ, Schaafsma MR, van Oers MH, Wijermans PW, Fibbe WE, Wittebol S, Schouten HC, van Marwijk Kooy M, Biesma DH, Baars JW, Slater R, Steijaert MM, Buijt I, Lokhorst HM; Dutch-Belgian Hemato-Oncology Cooperative Study Group.
Segeren CM, et al. Among authors: cornelissen jj.
Blood. 2003 Mar 15;101(6):2144-51. doi: 10.1182/blood-2002-03-0889. Epub 2002 Nov 27.
Blood. 2003.
PMID: 12456509
Free article.
Clinical Trial.